<?xml version='1.0' encoding='utf-8'?>
<document id="10411543"><sentence text="The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin."><entity charOffset="60-67" id="DDI-PubMed.10411543.s1.e0" text="digoxin" /><entity charOffset="72-80" id="DDI-PubMed.10411543.s1.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.10411543.s1.e0" e2="DDI-PubMed.10411543.s1.e0" /><pair ddi="false" e1="DDI-PubMed.10411543.s1.e0" e2="DDI-PubMed.10411543.s1.e1" /></sentence><sentence text="Recent data point to the contribution of P-glycoprotein (P-gp) to digoxin elimination" /><sentence text=" On the basis of clinical observations of patients in whom digoxin levels decreased considerably when treated with rifampin, we hypothesized that concomitant rifampin therapy may affect digoxin disposition in humans by induction of P-gp"><entity charOffset="59-66" id="DDI-PubMed.10411543.s3.e0" text="digoxin" /><entity charOffset="115-123" id="DDI-PubMed.10411543.s3.e1" text="rifampin" /><entity charOffset="158-166" id="DDI-PubMed.10411543.s3.e2" text="rifampin" /><entity charOffset="186-193" id="DDI-PubMed.10411543.s3.e3" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.10411543.s3.e0" e2="DDI-PubMed.10411543.s3.e0" /><pair ddi="false" e1="DDI-PubMed.10411543.s3.e0" e2="DDI-PubMed.10411543.s3.e1" /><pair ddi="false" e1="DDI-PubMed.10411543.s3.e0" e2="DDI-PubMed.10411543.s3.e2" /><pair ddi="false" e1="DDI-PubMed.10411543.s3.e0" e2="DDI-PubMed.10411543.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10411543.s3.e1" e2="DDI-PubMed.10411543.s3.e1" /><pair ddi="false" e1="DDI-PubMed.10411543.s3.e1" e2="DDI-PubMed.10411543.s3.e2" /><pair ddi="false" e1="DDI-PubMed.10411543.s3.e1" e2="DDI-PubMed.10411543.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10411543.s3.e2" e2="DDI-PubMed.10411543.s3.e2" /><pair ddi="false" e1="DDI-PubMed.10411543.s3.e2" e2="DDI-PubMed.10411543.s3.e3" /></sentence><sentence text=" We compared single-dose (1 mg oral and 1 mg intravenous) pharmacokinetics of digoxin before and after coadministration of rifampin (600 mg/d for 10 days) in 8 healthy volunteers"><entity charOffset="78-85" id="DDI-PubMed.10411543.s4.e0" text="digoxin" /><entity charOffset="123-131" id="DDI-PubMed.10411543.s4.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.10411543.s4.e0" e2="DDI-PubMed.10411543.s4.e0" /><pair ddi="false" e1="DDI-PubMed.10411543.s4.e0" e2="DDI-PubMed.10411543.s4.e1" /></sentence><sentence text=" Duodenal biopsies were obtained from each volunteer before and after administration of rifampin"><entity charOffset="88-96" id="DDI-PubMed.10411543.s5.e0" text="rifampin" /></sentence><sentence text=" The area under the plasma concentration time curve (AUC) of oral digoxin was significantly lower during rifampin treatment; the effect was less pronounced after intravenous administration of digoxin"><entity charOffset="66-73" id="DDI-PubMed.10411543.s6.e0" text="digoxin" /><entity charOffset="105-113" id="DDI-PubMed.10411543.s6.e1" text="rifampin" /><entity charOffset="192-199" id="DDI-PubMed.10411543.s6.e2" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.10411543.s6.e0" e2="DDI-PubMed.10411543.s6.e0" /><pair ddi="false" e1="DDI-PubMed.10411543.s6.e0" e2="DDI-PubMed.10411543.s6.e1" /><pair ddi="false" e1="DDI-PubMed.10411543.s6.e0" e2="DDI-PubMed.10411543.s6.e2" /><pair ddi="false" e1="DDI-PubMed.10411543.s6.e1" e2="DDI-PubMed.10411543.s6.e1" /><pair ddi="false" e1="DDI-PubMed.10411543.s6.e1" e2="DDI-PubMed.10411543.s6.e2" /></sentence><sentence text=" Renal clearance and half-life of digoxin were not altered by rifampin"><entity charOffset="34-41" id="DDI-PubMed.10411543.s7.e0" text="digoxin" /><entity charOffset="62-70" id="DDI-PubMed.10411543.s7.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.10411543.s7.e0" e2="DDI-PubMed.10411543.s7.e0" /><pair ddi="false" e1="DDI-PubMed.10411543.s7.e0" e2="DDI-PubMed.10411543.s7.e1" /></sentence><sentence text=" Rifampin treatment increased intestinal P-gp content 3"><entity charOffset="1-9" id="DDI-PubMed.10411543.s8.e0" text="Rifampin" /></sentence><sentence text="5 +/- 2" /><sentence text="1-fold, which correlated with the AUC after oral digoxin but not after intravenous digoxin"><entity charOffset="49-56" id="DDI-PubMed.10411543.s10.e0" text="digoxin" /><entity charOffset="83-90" id="DDI-PubMed.10411543.s10.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.10411543.s10.e0" e2="DDI-PubMed.10411543.s10.e0" /><pair ddi="false" e1="DDI-PubMed.10411543.s10.e0" e2="DDI-PubMed.10411543.s10.e1" /></sentence><sentence text=" P-gp is a determinant of the disposition of digoxin"><entity charOffset="45-52" id="DDI-PubMed.10411543.s11.e0" text="digoxin" /></sentence><sentence text=" Concomitant administration of rifampin reduced digoxin plasma concentrations substantially after oral administration but to a lesser extent after intravenous administration"><entity charOffset="31-39" id="DDI-PubMed.10411543.s12.e0" text="rifampin" /><entity charOffset="48-55" id="DDI-PubMed.10411543.s12.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.10411543.s12.e0" e2="DDI-PubMed.10411543.s12.e0" /><pair ddi="false" e1="DDI-PubMed.10411543.s12.e0" e2="DDI-PubMed.10411543.s12.e1" /></sentence><sentence text=" The rifampin-digoxin interaction appears to occur largely at the level of the intestine"><entity charOffset="5-13" id="DDI-PubMed.10411543.s13.e0" text="rifampin" /><entity charOffset="14-21" id="DDI-PubMed.10411543.s13.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.10411543.s13.e0" e2="DDI-PubMed.10411543.s13.e0" /><pair ddi="false" e1="DDI-PubMed.10411543.s13.e0" e2="DDI-PubMed.10411543.s13.e1" /></sentence><sentence text=" Therefore, induction of intestinal P-gp could explain this new type of drug-drug interaction" /><sentence text="" /></document>